Golden Pine Ventures Logo

Contact:
Christopher S. Meldrum, Managing Director
E-mail:

For Immediate Release

Pique Therapeutics launched in Research Triangle Park
– Golden Pine Ventures provides initial seed investment –

DURHAM, NC. -- Mar. 15, 2005 -- Pique Therapeutics, Inc., a development-stage biotechnology company, announced today that it has raised its first round of seed financing and established its headquarters in the Research Triangle Park area of Durham, North Carolina.

Pique Therapeutics seeks to become the leader in therapeutic vaccines, focused initially on the treatment of cancer. The Company’s lead product is a first-in-class therapeutic vaccine for non-small cell lung cancer and has completed Phase 1 clinical trials. Pique’s novel technology affords it the opportunity to create therapeutic vaccines for many additional areas of oncology, such as pancreatic cancer, colon cancer, and head and neck cancer.

In a Phase 1 study in 19 patients with stage IIIB/IV non-small cell lung cancer, the therapeutic vaccine was well tolerated and exhibited a good safety profile. Patients at this stage of disease have a median life expectancy of between 4 and 6 months. Of the nineteen cancer patients treated with the therapeutic vaccine, 77 percent survived for 6 months or longer, and nearly 50 percent of the patients survived for at least 18 months. Remarkably, 5 of these patients are still alive, 4 of them now in remission for more than 3 years.

Golden Pine Ventures helped to form Pique Therapeutics and provided an undisclosed amount of seed financing to launch the Company’s development efforts.

The Company was founded on the research of Dr. Eckhard R. Podack, M.D., Ph.D., who is Chair of the Department of Immunology and Microbiology at the University of Miami. Dr. Podack, who is also the Associate Director of the Sylvester Comprehensive Cancer Center, will serve as Chief Scientific Director of Pique Therapeutics.

The Company will be led by Dr. Podack, and Christopher S. Meldrum, Managing Director at Golden Pine Ventures. Mr. Meldrum will serve as President of Pique Therapeutics.

Golden Pine Ventures, LLC, was founded in 2004, in Research Triangle Park, North Carolina. The Company’s mission is to aggressively seek out state-of-the-art technologies developed by leading researchers and grow them into substantial businesses.

About Pique Therapeutics
Pique Therapeutics is a biotechnology company seeking to become the leader in therapeutic vaccines, focused initially on the treatment of cancer. The company's lead product is a first-in-class therapeutic vaccine for non-small cell lung cancer and has completed Phase 1 clinical trials. Pique’s novel technology affords it the opportunity to create therapeutic vaccines for many additional areas of oncology, such as pancreatic cancer, colon cancer, and head and neck cancer. www.piquetherapeutics.com.

About CED
The Council for Entrepreneurial Development (CED) is a private, non-profit organization formed in 1984 to identify, enable and promote high growth, high impact entrepreneurial companies and to accelerate the entrepreneurial culture of the Research Triangle and North Carolina. CED is the largest and oldest entrepreneurial support organization in the nation with more than 4,000 members representing over 1,100 entrepreneurial companies, financiers and professional firms. In July 2005, Wilmington’s Coastal Entrepreneurial Council merged with CED to create CED-Coastal, a divisional office focused on entrepreneurial development in Wilmington and throughout North Carolina’s entire coastal region. CED provides education, mentoring and capital formation resources to new and existing high-growth entrepreneurs through annual conferences, seminars, workshops and programs on entrepreneurial management and finance. www.cednc.org.

About Golden Pine Ventures, LLC
Golden Pine Ventures works with scientists and entrepreneurs to form new portfolio companies, provides the necessary business and management expertise, funds all initial working capital needs, and raises high-valuation follow-on rounds of financing.  Current Golden Pine Ventures’ portfolio companies include: Pique Therapeutics, Kylin Therapeutics, and Exigent Pharmaceuticals.  For more information, please visit www.goldenpineventures.com